1. An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer. Issue 7 (July 2016) Authors: Merseburger, Axel; Hupe, Marie Journal: Advances in therapy Issue: Volume 33:Issue 7(2016) Page Start: 1072 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Foreword. Issue 1 (2019) Authors: Merseburger, Axel Journal: European oncology & haematology Issue: Volume 15:Issue 1(2019) Page Start: 13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Foreword. Issue 1 (2020) Authors: Merseburger, Axel Journal: European oncology & haematology Issue: Volume 16:Issue 1(2020) Page Start: 11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Foreword. Issue 1 (2021) Authors: Kumar, Shaji K; Merseburger, Axel Journal: Touch reviews in oncology & haematology Issue: Volume 17:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Foreword. Issue 2 (2019) Authors: Merseburger, Axel Journal: European oncology & haematology Issue: Volume 15:Issue 2(2019) Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Issue 7 (July 2021) Authors: Powles, Thomas; Csőszi, Tibor; Özgüroğlu, Mustafa; Matsubara, Nobuaki; Géczi, Lajos; Cheng, Susanna Y-S; Fradet, Yves; Oudard, Stephane; Vulsteke, Christof; Morales Barrera, Rafael; Fléchon, Aude; Gunduz, Seyda; Loriot, Yohann; Rodriguez-Vida, Alejo; Mamtani, Ronac; Yu, Evan Y; Nam, Kijoeng; Imai... Journal: Lancet oncology Issue: Volume 22:Issue 7(2021) Page Start: 931 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9 (September 2022) Authors: Powles, Thomas; Tomczak, Piotr; Park, Se Hoon; Venugopal, Balaji; Ferguson, Thomas; Symeonides, Stefan N; Hajek, Jaroslav; Gurney, Howard; Chang, Yen-Hwa; Lee, Jae Lyun; Sarwar, Naveed; Thiery-Vuillemin, Antoine; Gross-Goupil, Marine; Mahave, Mauricio; Haas, Naomi B; Sawrycki, Piotr; Burgents, Jo... Journal: Lancet oncology Issue: Volume 23:Issue 9(2022) Page Start: 1133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Segmental dosimetry, toxicity and long‐term outcome in patients with prostate cancer treated with permanent seed implants. (10th January 2013) Authors: Meyer, Andreas; Wassermann, Julia; Warszawski‐Baumann, Antje; Baumann, Rolf; Machtens, Stefan; Karstens, Johann H.; Christiansen, Hans; Merseburger, Axel; Kuczyk, Markus A.; von, Christoph Journal: BJU international Issue: Volume 111:Number 6(2013:Mar.) Page Start: 897 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. True Incidence of Gleason 6 Pathology in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC). Issue 1 (January 2017) Authors: Böker, Alena; Kuczyk, Markus; Kramer, Mario; Merseburger, Axel; Krüger, Katharina; Imkamp, Florian; Klot, Christoph Journal: Advances in therapy Issue: Volume 34:Issue 1(2017) Page Start: 171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗